146 related articles for article (PubMed ID: 23455457)
1. PU.1 is a tumor suppressor for B cell malignancies.
Okuno Y; Yuki H
Oncotarget; 2012 Dec; 3(12):1495-6. PubMed ID: 23455457
[No Abstract] [Full Text] [Related]
2. Editorial: Mouse Models of B Cell Malignancies.
Perez-Chacon G; Vincent-Fabert C; Zapata JM
Front Immunol; 2021; 12():789901. PubMed ID: 34777400
[No Abstract] [Full Text] [Related]
3. Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Lim M; Batista CR; de Oliveira BR; Creighton R; Ferguson J; Clemmer K; Knight D; Iansavitchous J; Mahmood D; Avino M; DeKoter RP
Mol Cell Biol; 2020 Aug; 40(18):. PubMed ID: 32631903
[TBL] [Abstract][Full Text] [Related]
4. Bruton Tyrosine Kinase Degraders in B-Cell Malignancies.
Huynh T; Rodriguez-Rodriguez S; Danilov AV
Mol Cancer Ther; 2024 May; 23(5):619-626. PubMed ID: 38693903
[No Abstract] [Full Text] [Related]
5. The A-myb transcription factor in neoplastic and normal B cells.
Golay J; Facchinetti V; Ying G; Introna M
Leuk Lymphoma; 1997 Jul; 26(3-4):271-9. PubMed ID: 9322889
[TBL] [Abstract][Full Text] [Related]
6. PU.1 binding to the p53 family of tumor suppressors impairs their transcriptional activity.
Tschan MP; Reddy VA; Ress A; Arvidsson G; Fey MF; Torbett BE
Oncogene; 2008 May; 27(24):3489-93. PubMed ID: 18193090
[TBL] [Abstract][Full Text] [Related]
7. PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.
Yuki H; Ueno S; Tatetsu H; Niiro H; Iino T; Endo S; Kawano Y; Komohara Y; Takeya M; Hata H; Okada S; Watanabe T; Akashi K; Mitsuya H; Okuno Y
Blood; 2013 Feb; 121(6):962-70. PubMed ID: 23212521
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of Bcl-2 family for treatment of B-cell malignancies.
Huang J; Fairbrother W; Reed JC
Expert Rev Hematol; 2015 Jun; 8(3):283-97. PubMed ID: 25912824
[TBL] [Abstract][Full Text] [Related]
9. B-cell tumor development in
Mouly E; Ghamlouch H; Della-Valle V; Scourzic L; Quivoron C; Roos-Weil D; Pawlikowska P; Saada V; Diop MK; Lopez CK; Fontenay M; Dessen P; Touw IP; Mercher T; Aoufouchi S; Bernard OA
Blood Adv; 2018 Mar; 2(6):703-714. PubMed ID: 29581109
[TBL] [Abstract][Full Text] [Related]
10. Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy.
Uranishi M; Iida S; Sanda T; Ishida T; Tajima E; Ito M; Komatsu H; Inagaki H; Ueda R
Leukemia; 2005 Aug; 19(8):1471-8. PubMed ID: 15959530
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the PU.1 gene in chicken B lymphoma DT40 cells and its effect on reported target gene expression.
Matsudo H; Otsuka A; Ozawa Y; Ono M
Gene; 2003 Dec; 322():169-74. PubMed ID: 14644508
[TBL] [Abstract][Full Text] [Related]
12. Essential role of stromally induced hedgehog signaling in B-cell malignancies.
Dierks C; Grbic J; Zirlik K; Beigi R; Englund NP; Guo GR; Veelken H; Engelhardt M; Mertelsmann R; Kelleher JF; Schultz P; Warmuth M
Nat Med; 2007 Aug; 13(8):944-51. PubMed ID: 17632527
[TBL] [Abstract][Full Text] [Related]
13. Tcl1 interacts with Atm and enhances NF-κB activation in hematologic malignancies.
Gaudio E; Spizzo R; Paduano F; Luo Z; Efanov A; Palamarchuk A; Leber AS; Kaou M; Zanesi N; Bottoni A; Costinean S; Rassenti LZ; Nakamura T; Kipps TJ; Aqeilan RI; Pekarsky Y; Trapasso F; Croce CM
Blood; 2012 Jan; 119(1):180-7. PubMed ID: 22065599
[TBL] [Abstract][Full Text] [Related]
14. Conditional TPM3-ALK and NPM-ALK transgenic mice develop reversible ALK-positive early B-cell lymphoma/leukemia.
Giuriato S; Foisseau M; Dejean E; Felsher DW; Al Saati T; Demur C; Ragab A; Kruczynski A; Schiff C; Delsol G; Meggetto F
Blood; 2010 May; 115(20):4061-70. PubMed ID: 20223922
[TBL] [Abstract][Full Text] [Related]
15. A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia.
dos Santos NR; Ghysdael J
Leukemia; 2006 Jan; 20(1):182-5. PubMed ID: 16281066
[No Abstract] [Full Text] [Related]
16. Neoplastic B-cell growth is impaired by HLA-G/ILT2 interaction.
Naji A; Menier C; Maki G; Carosella ED; Rouas-Freiss N
Leukemia; 2012 Aug; 26(8):1889-92. PubMed ID: 22441169
[No Abstract] [Full Text] [Related]
17. PU.1 binds to a distal regulatory element that is necessary for B cell-specific expression of CIITA.
Yoon H; Boss JM
J Immunol; 2010 May; 184(9):5018-28. PubMed ID: 20363966
[TBL] [Abstract][Full Text] [Related]
18. Molecular detection of B-cell neoplasms by specific DNA methylation biomarkers.
Wang MX; Wang HY; Zhao X; Srilatha N; Zheng D; Shi H; Ning J; Duff DJ; Taylor KH; Gruner BA; Caldwell CW
Int J Clin Exp Pathol; 2010 Jan; 3(3):265-79. PubMed ID: 20224725
[TBL] [Abstract][Full Text] [Related]
19. The emerging role of estrogen in B cell malignancies.
Ladikou EE; Kassi E
Leuk Lymphoma; 2017 Mar; 58(3):528-539. PubMed ID: 27557932
[TBL] [Abstract][Full Text] [Related]
20. Expression of the two alternative [a] and [b] transcripts of CCND1 gene in cyclin D1-expressing B-malignancies: relevance for the pathogenesis.
Roué G; Krieger S; Florent M; Roussel M; Duquesne F; Troussard X; Pichereau V; Sola B
Leukemia; 2003 Mar; 17(3):652-5. PubMed ID: 12646964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
